Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-α and ribavirin in HIV/HCV co-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 303-306

  Vargas, Ana ^a   Berenguer, Juan ^b   Catalán, Pilar ^b   Miralles, Pilar ^b   López, Juan Carlos ^b   Cosín, Jaime ^b   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antiviral therapy; Chemokines; Chronic hepatitis C; Inflammation; Liver; Prognostic marker; Th2 response; Viral load

Indexed keywords

EOTAXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 77950221931     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp454     Document Type: Article

References (14)

1. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008; 47: 94-101.
2. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009; 49: 676-88.
3. Wald O,Weiss ID, Galun E et al. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine 2007; 39: 50-62.
4. Romero AI, Lagging M, Westin J et al. Interferon (IFN)-γ-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
5. Diago M, Castellano G, Garcia-Samaniego J et al. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374-9.
6. Berenguer J, Bellon JM, Miralles P et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007; 14: 859-69.
7. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
8. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
9. Moser B, Wolf M, Walz A et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 75-84.
10. Leroy V, Vigan I, Mosnier JF et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003; 38: 829-41.
11. Davis AM, Hagan KA, Matthews LA et al. Blockade of virus infection by human CD4+ T cells via a cytokine relay network. J Immunol 2008; 180: 6923-32.
12. Younossi ZM, Baranova A, Afendy A et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009; 49: 763-74.
13. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-9.
14. Polyak SJ. Hepatitis C virus-cell interactions and their role in pathogenesis. Clin Liver Dis 2003; 7: 67-88.